Voglibose analysis as per IP and JP

Voglibose, an alpha-glucosidase inhibitor, is effectively used for diabetes treatment. It delays glucose absorption at the intestinal level and thereby prevents a sudden surge of glucose after a meal. It was developed in 1994 in Japan by Takeda Pharmaceuticals Industries Ltd. And shows high activity so small doses can effectively prevent side effects in the gastrointestinal tract.

620px-Voglibose_structure.svg
Structure of Voglibose

The absence of a chromophore or conjugation in the molecule makes it difficult to detect by spectroscopic absorption in the UV – Visible region. However, post-column derivatization with a fluorescence agent provides a high sensitivity and selectivity for Voglibose in pharmaceutical formulations. This method has also been notified in Japanese Pharmacopoeia 16th edition as well as Indian Pharmacopoeia 2014.

We have introduced a post-column fluorescence derivatization system and the test conditions employed are

  • Column- SS amino column 250mmX4.6mmX5μ
  • Column temperature- [latex]25^0[/latex]C.
  • Mobile phase-37:63 mixture of phosphate buffer at ph 6.5 and acetonitrile
  • Flow rate – 0.6ml/min
  • Reaction coil temperature- [latex]100^0[/latex]C
  • Detector- Fluorescence with excitation at 350nm and excitation at 430nm
  • Fluorescence agent-Taurine 6.25 g +2.56 g Sodium periodate in 1000ml water

The method provides high precision and sensitivity of detection.

Please feel free to contact us using the contact form or call us now on +91-8588851888 and we will be happy to provide you with a proposal for testing your Voglibose products and raw material samples.

Get a Free proposal!

Send us your requirement and our team of experts will find the best solution for you and send you a proposal free of cost!